PMID- 23080504
OWN - NLM
STAT- MEDLINE
DCOM- 20130326
LR  - 20181202
IS  - 1096-9071 (Electronic)
IS  - 0146-6615 (Linking)
VI  - 84
IP  - 12
DP  - 2012 Dec
TI  - Response to valganciclovir in chronic fatigue syndrome patients with human 
      herpesvirus 6 and Epstein-Barr virus IgG antibody titers.
PG  - 1967-74
LID - 10.1002/jmv.23411 [doi]
AB  - Valganciclovir has been reported to improve physical and cognitive symptoms in 
      patients with chronic fatigue syndrome (CFS) with elevated human herpesvirus 6 
      (HHV-6) and Epstein-Barr virus (EBV) IgG antibody titers. This study investigated 
      whether antibody titers against HHV-6 and EBV were associated with clinical 
      response to valganciclovir in a subset of CFS patients. An uncontrolled, 
      unblinded retrospective chart review was performed on 61 CFS patients treated 
      with 900 mg valganciclovir daily (55 of whom took an induction dose of 1,800 mg 
      daily for the first 3 weeks). Antibody titers were considered high if HHV-6 IgG >/= 
      1:320, EBV viral capsid antigen (VCA) IgG >/= 1:640, and EBV early antigen (EA) IgG 
      >/= 1:160. Patients self-rated physical and cognitive functioning as a percentage 
      of their functioning prior to illness. Patients were categorized as responders if 
      they experienced at least 30% improvement in physical and/or cognitive 
      functioning. Thirty-two patients (52%) were categorized as responders. Among 
      these, 19 patients (59%) responded physically and 26 patients (81%) responded 
      cognitively. Baseline antibody titers showed no significant association with 
      response. After treatment, the average change in physical and cognitive 
      functioning levels for all patients was +19% and +23%, respectively (P < 0.0001). 
      Longer treatment was associated with improved response (P = 0.0002). No 
      significant difference was found between responders and non-responders among 
      other variables analyzed. Valganciclovir treatment, independent of the baseline 
      antibody titers, was associated with self-rated improvement in physical and 
      cognitive functioning for CFS patients who had positive HHV-6 and/or EBV 
      serologies. Longer valganciclovir treatment correlated with an improved response.
CI  - Copyright (c) 2012 Wiley Periodicals, Inc.
FAU - Watt, Tessa
AU  - Watt T
AD  - Division of Infectious Diseases and Geographic Medicine, Department of Medicine, 
      Stanford University Medical Center, Palo Alto, CA, USA.
FAU - Oberfoell, Stephanie
AU  - Oberfoell S
FAU - Balise, Raymond
AU  - Balise R
FAU - Lunn, Mitchell R
AU  - Lunn MR
FAU - Kar, Aroop K
AU  - Kar AK
FAU - Merrihew, Lindsey
AU  - Merrihew L
FAU - Bhangoo, Munveer S
AU  - Bhangoo MS
FAU - Montoya, Jose G
AU  - Montoya JG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
RN  - 0 (Antibodies, Viral)
RN  - 0 (Antigens, Viral)
RN  - 0 (Antiviral Agents)
RN  - 0 (Capsid Proteins)
RN  - 0 (Epstein-Barr viral capsid antigen)
RN  - 0 (Epstein-Barr virus early antigen)
RN  - GCU97FKN3R (Valganciclovir)
RN  - P9G3CKZ4P5 (Ganciclovir)
SB  - IM
MH  - Adult
MH  - Antibodies, Viral/*blood/immunology
MH  - Antigens, Viral/analysis/immunology
MH  - Antiviral Agents/administration & dosage/*therapeutic use
MH  - Capsid Proteins/analysis/immunology
MH  - Cognition/drug effects
MH  - Drug Administration Schedule
MH  - Drug Evaluation
MH  - Fatigue Syndrome, Chronic/*drug therapy/immunology/virology
MH  - Female
MH  - Ganciclovir/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Herpesvirus 4, Human/*immunology
MH  - Herpesvirus 6, Human/*immunology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Self Report
MH  - Treatment Outcome
MH  - Valganciclovir
EDAT- 2012/10/20 06:00
MHDA- 2013/03/27 06:00
CRDT- 2012/10/20 06:00
PHST- 2012/10/20 06:00 [entrez]
PHST- 2012/10/20 06:00 [pubmed]
PHST- 2013/03/27 06:00 [medline]
AID - 10.1002/jmv.23411 [doi]
PST - ppublish
SO  - J Med Virol. 2012 Dec;84(12):1967-74. doi: 10.1002/jmv.23411.